Results 141 to 150 of about 2,377 (150)

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes

European Journal of Clinical Pharmacology, 2019
Felix Huth, Kasra Shakeri-Nejad, Anne Gardin   +2 more
exaly  

MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod)

ChemMedChem, 2015
Yves P Auberson, Emmanuelle Briard, Joel A Krauser   +2 more
exaly  

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

European Journal of Clinical Pharmacology, 2018
Felix Huth, Kasra Shakeri-Nejad, Anne Gardin   +2 more
exaly  

Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects

Clinical Therapeutics, 2016
Kasra Shakeri-Nejad, Eric Legangneux
exaly  

Siponimod in the treatment of multiple sclerosis

Expert Opinion on Investigational Drugs, 2019
Andrew K. Goodman, Nidhiben Anadani
exaly  

Siponimod for the treatment of secondary progressive multiple sclerosis

Expert Opinion on Pharmacotherapy, 2019
Laura Dumitrescu, Cris Constantinescu, Radu Tanasescu   +2 more
exaly  

In Vivo Ocular Pharmacokinetics and Toxicity of Siponimod in Albino Rabbits

Molecular Pharmaceutics
Christian Waeber, Katie B. Ryan, Rasha A Alshaikh   +2 more
exaly  

Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis

Multiple Sclerosis Journal
Chris Gilmartin, Christopher Tench, Afagh Garjani   +2 more
exaly  

Siponimod inhibits microglial inflammasome activation

Neuroscience Research
Hideyuki Takeuchi, Fumiaki Tanaka, Akihiro Ogasawara   +2 more
exaly  

The real-world safety assessment of Siponimod: A systematic analysis based on the FAERS database

Journal of the Neurological Sciences
Haohao Zhu, Rongrong Lu
exaly